Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) reached a new 52-week low during trading on Monday . The company traded as low as $2.65 and last traded at $2.65, with a volume of 167,367 shares changing hands. The stock had previously closed at $2.70.

A number of analysts recently commented on the company. Jefferies Group LLC set a $5.00 price objective on Xenon Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, August 4th. Canaccord Genuity reiterated a “buy” rating and set a $5.00 price objective on shares of Xenon Pharmaceuticals in a research report on Tuesday, June 27th. Finally, Zacks Investment Research upgraded Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, July 1st. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $11.88.

The stock’s market capitalization is $45.89 million. The company’s 50 day moving average price is $3.23 and its 200-day moving average price is $5.08.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.38) by $0.03. The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.38 million. Xenon Pharmaceuticals had a negative return on equity of 47.53% and a negative net margin of 3,489.63%. On average, equities analysts forecast that Xenon Pharmaceuticals Inc. will post ($0.96) EPS for the current year.

In related news, insider Value Fund L. P. Biotechnology acquired 85,461 shares of Xenon Pharmaceuticals stock in a transaction on Tuesday, June 27th. The stock was acquired at an average price of $4.00 per share, for a total transaction of $341,844.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Value Fund L. P. Biotechnology acquired 358,698 shares of Xenon Pharmaceuticals stock in a transaction on Wednesday, June 7th. The shares were bought at an average price of $3.81 per share, with a total value of $1,366,639.38. The disclosure for this purchase can be found here. Insiders purchased a total of 495,978 shares of company stock valued at $1,906,534 in the last 90 days. 9.40% of the stock is currently owned by company insiders.

Several institutional investors have recently added to or reduced their stakes in XENE. K2 Principal Fund L.P. raised its position in Xenon Pharmaceuticals by 40.6% in the second quarter. K2 Principal Fund L.P. now owns 164,510 shares of the biopharmaceutical company’s stock worth $518,000 after buying an additional 47,535 shares during the last quarter. Endurant Capital Management LP bought a new position in Xenon Pharmaceuticals during the first quarter worth $1,363,000. Sabby Management LLC bought a new position in Xenon Pharmaceuticals during the first quarter worth $1,186,000. KCG Holdings Inc. bought a new position in Xenon Pharmaceuticals during the first quarter worth $122,000. Finally, Renaissance Technologies LLC raised its position in Xenon Pharmaceuticals by 90.1% in the first quarter. Renaissance Technologies LLC now owns 217,090 shares of the biopharmaceutical company’s stock worth $868,000 after buying an additional 102,890 shares during the last quarter. Institutional investors and hedge funds own 56.01% of the company’s stock.

TRADEMARK VIOLATION WARNING: This news story was published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.watchlistnews.com/xenon-pharmaceuticals-inc-xene-sets-new-12-month-low-at-2-65/1487250.html.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD).

Receive News & Ratings for Xenon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.